福巴替尼治疗后复发的可能性大吗？

Generally, the possibility of recurrence after treatment with forbatinib is unlikely. However, since each patient's condition is different and their response to the efficacy of forbatinib is also different, the data on the possibility of recurrence after treatment with forbatinib cannot be clear. The risk and possibility of recurrence vary from patient to patient.

Forbatinib treats diseases

It is a targeted therapy drug for specific types of intrahepatic cholangiocarcinoma (iCCA), especially those carrying FGFR2 gene fusions or rearrangements. It mainly works by inhibiting the action of progesterate dehydrogenase 2 (PD-L1).

Possibility of relapse after fobatinib treatment

The possibility of relapse after fobatinib treatment usually depends on multiple factors, including the patient's specific condition, the subtype of the disease, the initial treatment effect of the disease, the patient's age, health status, and whether there are genetic or molecular abnormalities.

Although forbatinib can significantly improve the progression-free survival (PFS) of patients, not all patients can maintain stable disease for a long time, and recurrence is still possible, but the specific percentage of recurrence is not yet clear.

In clinical studies, some patients treated with forbatinib achieved remission, but some patients relapsed after treatment. The risk factors and timing of relapse vary from person to person; some patients may relapse within months of treatment and others may not relapse for years after treatment.

What to do after relapse after fobatinib treatment

1. Individualized treatment: Once relapse occurs, the doctor will adjust the treatment plan according to the patient's specific situation, and may replace other targeted drugs, chemotherapy or other supportive treatments.

2. Secondary treatment: For some patients, if relapse occurs after treatment with forbatinib, doctors may consider using forbatinib again, especially if the patient has a good response to the initial treatment.

3. Clinical trials: Participating in clinical new drug trials may be another option, especially when standard treatments are ineffective, clinical trials may provide new therapeutic drugs or methods.

4. Supportive treatment: When treating relapse, supportive treatment, such as pain management, nutritional support, and psychological support, is equally important to improve the patient's quality of life.

Efficacy of fobatinib

Forbatinib demonstrated an overall response rate (ORR) of 42% in patients with previously treated locally advanced or metastatic intrahepatic cholangiocarcinoma, with a median duration of response (mDoR) of nearly 10 months. Among them, 72% of responders (n=31) had a response lasting ≥6 months, and 14% of responders (n=6) had a response lasting ≥1 year.

In a non-prespecified follow-up analysis conducted 8 months after the primary analysis, efficacy in the overall study population was maintained at an ORR of 41.7%, a DCR of 82.5%, a median DoR of 9.5 months, a median PFS of 8.9 months, and a median OS of 20 months.

Forbatinib dosage and administration

1. Before starting forbatinib treatment, confirm the presence of FGFR2 gene fusion or other rearrangements.

2. The recommended dose is 20 mg, which is five 4 mg tablets, once a day until disease progression or unacceptable toxicity occurs.

3. Forbatinib tablets should be swallowed whole, with or without food.

(Note: The above dosage and administration reference are from the U.S. FDA drug instructions. The usage and dosage are for reference only, and the specific needs are subject to medical advice)

Summary

The treatment strategy for recurrence after forbatinib treatment should be formulated by professional doctors based on the patient's condition and treatment response. Patients should follow the doctor's advice and actively cooperate with the doctor's treatment to control the condition as soon as possible and improve the tongue's quality of life.

Recommended hot articles: